Roche's Sequencing Sales Decline 15 Percent in Q1
April 20, 2010
Roche's Sequencing Sales Decline 15 Percent in Q1
The year-over-year decline in first-quarter sequencing revenues follows a year of stagnation: for full-year 2009, Roche's Applied Science group reported flat overall sales for DNA sequencing systems, though sequencing reagent sales were up 26 percent.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- For 454 Technology, Roche Bets on Specific Apps, Taking Share from Sanger
August 10, 2010 / In Sequence - 454 GS Junior Drives 1 Percent Growth in Roche's Sequencing, Array Business in Q1
April 19, 2011 / In Sequence - Roche and Fluidigm to Co-Market 454's Sequencers, Fluidigm's Multiplexed PCR Arrays
October 19, 2010 / In Sequence - Roche's Sequencing and Array Sales Grow 10 Percent Combined in H1
July 27, 2010 / In Sequence - Roche and IBM to Co-Develop, Commercialize IBM's DNA Transistor Technology for Nanopore Sequencing
July 6, 2010 / In Sequence